Item 5.07 Submission of Matters to a Vote of Security Holders

The Company conducted its annual stockholders' meeting on January 31, 2023.

At the annual meeting, 501,078,193 shares were represented (91.7 percent of the 546,347,256 shares outstanding and entitled to vote). Five items were considered at the meeting and the results of the voting were as follows:



1.Election of Directors: The nominees in the proxy statement were: Prama Bhatt,
Gary C. Bhojwani, Stephen M. Lacy, Elsa A. Murano, Ph.D., Susan K. Nestegard,
William A. Newlands, Christopher J. Policinski, Jose Luis Prado, Sally J. Smith,
James P. Snee, and Steven A. White. The results were as follows:
DIRECTOR:                        FOR         AGAINST      ABSTAIN    BROKER NON-VOTE
Prama Bhatt                  462,682,222    2,656,200     615,915      35,123,856
Gary C. Bhojwani             431,658,836    33,861,891    433,610      35,123,856
Stephen M. Lacy              442,535,774    23,024,674    393,889      35,123,856
Elsa A. Murano, Ph.D.        457,109,309    8,431,017     414,011      35,123,856
Susan K. Nestegard           456,931,326    8,549,676     473,335      35,123,856
William A. Newlands          462,501,732    3,017,270     435,335      35,123,856
Christopher J. Policinski    459,824,596    5,750,039     379,702      35,123,856
Jose Luis Prado              463,381,581    2,147,040     425,716      35,123,856
Sally J. Smith               461,538,698    3,981,669     433,970      35,123,856
James P. Snee                452,722,730    10,163,567   3,068,040     35,123,856
Steven A. White              453,354,194    12,217,025    383,118      35,123,856



2. Ratification of the appointment of Ernst & Young LLP as the Company's
independent registered public accounting firm for the fiscal year ending October
29, 2023:


                              For:             490,062,300
                              Against:          10,521,289
                              Abstain:             494,604

3. Advisory vote to approve the Company's Named Executive Officer compensation as disclosed in the Company's 2023 annual meeting proxy statement (as filed with the Securities and Exchange Commission on December 21, 2022):




                          For:                     453,374,829
                          Against:                  11,351,300
                          Abstain:                   1,228,208
                          Broker Non-Vote:          35,123,856





                                       2

--------------------------------------------------------------------------------




4. Advisory vote to determine the frequency of the stockholder advisory vote to
approve Named Executive Officer compensation set forth in the Company's proxy
statement:


                         Every Year:                460,832,645
                         Every Two Years:               428,255
                         Every Three Years:           3,927,412
                         Abstain:                       766,025
                         Broker Non-Vote:            35,123,856

In light of the voting results for this item, the Company's Board of Directors determined that it will hold a stockholder advisory vote on the compensation of the Company's Named Executive Officers every year.

5. Stockholder proposal requesting the Company comply with World Health Organization guidelines on antimicrobial use throughout its supply chains:




                          For:                      27,382,976
                          Against:                 436,218,732
                          Abstain:                   2,352,629
                          Broker Non-Vote:          35,123,856


                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses